AD71 s.r.o

Running trials

• Enrolling by invitation

  ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

  NCT06194799· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· Source

• Completed

  A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.

  2023-508163-74-00· Phase 3· Source

• Completed

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· Phase 3· Source

• Completed

  A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

  NCT05318976· Phase 2· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Source

• Completed

  A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

  NCT04829318· Phase 4· Source

• Completed

  A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

  NCT04521478· Phase 2· Source